Correction of sexual dysfunction in postmenopausal women

Keywords: sexual dysfunction, correction, postmenopausal age.


Annotation. In the postmenopausal age, the quality of sexual life deteriorates significantly. To date, there are no effective methods for correcting sexual dysfunction (SD) in women of this age. The aim of the study was to compare the clinical efficacy of traditional drugs for menopausal hormone therapy (MHT) – tibolone and a complex drug containing 1 mg of estradiol and 5 mg of dydrogesterone for SD in postmenopausal women. 69 postmenopausal women with SD were monitored: 37 – the main group (MG), 32 – the comparison group (CG). MG women were treated a drug’s containing tibolone, 1 pill once a day. Women with CG were prescribed traditional menopausal hormone therapy (MHT) with a drug containing 1 mg of estradiol and 5 mg of dydrogesterone. The quality of sexual life was determined before treatment and 1 month after treatment using a specially designed questionnaire and menopause rating scale (MRS). Statistics were processed using LibreOffice Calc (Mozilla Public License v 2.0). Quantitative data from the two related groups (before and after treatment) were compared using the Wilcoxon signed rank test. When considering the results in an alternative form (the presence or absence of a certain feature used Fisher's angular transformation. Pairwise comparisons of groups were performed using the Mann-Whitney test at p <0,05. In the treatment of SD in women with MG there was a reduction of all symptoms; in patients with CG - improvement of only one indicator was observed. In MG, after 1month treatment of SD, the number of women satisfied with their sexual life increased 2.4 times (p<0.05), and in CG – 1.4 times (p>0.05). Significant reduction in most menopausal symptoms was observed in both groups of women after treatment. According to psychoneurological indicators and atrophic changes of the vagina, the difference between MG and CG after treatment was not detected (p>0.05). Besides, the best correction of climacteric vegetative disorders in CG was found in comparison with MG (p<0.05). In MG has been noted significant improvement in physical and mental health disorders and joint and muscle discomfort compared with СG (p <0.05). Recovery of urinary disorders during a month of therapy with MHT drugs was not observed in any group of studied women. Thus, the drug based on tibolone can be recommended for the correction of sexual dysfunction in postmenopausal women.


[1] Angelou, K., Grigoriadis, T., Diakosavvas, M., Zacharakis, D., & Athanasiou, S. (2020). The Genitourinary Syndrome of Menopause: An Overview of the Recent Data. Cureus, 12(4), e7586.

[2] Chou, J., Kiebalo, T., Jagiello, P., & Pawlaczyk, K. (2021). Multifaceted Sexual Dysfunction in Dialyzing Men and Women: Pathophysiology, Diagnostics, and Therapeutics. Life (Basel, Switzerland), 11(4), 311.

[3] Cobin, R. H., & Goodman, N. F. (2017). American association of clinical endocrinologists and American college of endocrinology position statement on menopause-2017 update. Endocrine practice: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 23(7), 869-880.

[4] de Villiers, T. J., Pines, A., Panay, N., Gambacciani, M., Archer, D. F., Baber, R. J., … & Sturdee, D. W. (2013). Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric: the journal of the International Menopause Society, 16(3), 316-337.

[5] Fisher, J. S., Rezk, A., Nwefo, E., Masterson, J., & Ramasamy, R. (2020). Sexual Health in the Elderly Population. Current sexual health reports, 12(4), 381-388.

[6] Formoso, G., Perrone, E., Maltoni, S., Balduzzi, S., Wilkinson, J., Basevi, V., … & Maestri, E. (2016). Short-term and long-term effects of tibolone in postmenopausal women. The Cochrane database of systematic reviews, 10(10), CD008536.

[7] Gregersen, N., Jensen, P. T., & Giraldi, A. E. (2006). Sexual dysfunction in the peri- and postmenopause. Status of incidence, pharmacological treatment and possible risks. A secondary publication. Danish medical bulletin, 53(3), 349-353.

[8] Heidari, M., Ghodusi, M., Rezaei, P., Kabirian Abyaneh, S., Sureshjani, E. H., & Sheikhi, R. A. (2019). Sexual Function and Factors Affecting Menopause: A Systematic Review. Journal of menopausal medicine, 25(1), 15-27.

[9] Heinemann, L.A., DoMinh, T., Strelow, F., Gerbsch, S., Schnitker, J., & Schneider, H. (2004). The Menopause Rating Scale (MRS) as outcome measure for hormone treatment? A validation study. Health Qual Life Outcomes, 2, 67.

[10] Jannini, E. A., & Nappi, R. E. (2018). Couplepause: A New Paradigm in Treating Sexual Dysfunction During Menopause and Andropause. Sexual medicine reviews, 6(3), 384-395.

[11] Kapoor, E., Kling, J. M., Lobo, A. S., & Faubion, S. S. (2021). Menopausal hormone therapy in women with medical conditions. Best practice & research. Clinical endocrinology & metabolism, 35(6), 101578.

[12] Lange, K. (2002). Mathematical and Statistical Methods for Genetic Analysis. (2th ed.). New York: Springer-Verlag. DOI 10.1007/978-0-387-21750-5

[13] Lv, Y., Liu, Y., Wang, Y., Kong, F., Pang, Q., & Hu, G. (2021). CCDC114, DNAI2 and TOP2A involves in the effects of tibolone treatment on postmenopausal endometrium. BMC women's health, 21(1), 240.

[14] Nazarpour, S., Simbar, M., Khorrami, M., Jafari Torkamani, Z., Saghafi, R., & Alavi-Majd, H. (2021). The association between sexual function and body image among postmenopausal women: a cross-sectional study. BMC women's health, 21(1), 403.

[15] Parish, S. J., Simon, J. A., Davis, S. R., Giraldi, A., Goldstein, I., Goldstein, S. W., … & Vignozzi, L. (2021). International Society for the Study of Women’s Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. Journal of women’s health (2002), 30(4), 474-491.

[16] Rosen, R., Brown, C., Heiman, J., Leiblum, S., Meston, C., Shabsigh, R., … & D'Agostino, R., Jr (2000). The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. Journal of sex & marital therapy, 26(2), 191-208.

[17] Shams, T., Firwana, B., Habib, F., Alshahrani, A., Alnouh, B., Murad, M. H., & Ferwana, M. (2014). SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials. Journal of general internal medicine, 29(1), 204-213.

[18] Vaskiv, О., Grigorenko, А., Horbatiuk, О., Shatkovska, A., & Binkovska, А. (2019). Peculiarities of hormonal homeostasis in perimenopausal and postmenopausal women with menopausal disorders. Biomedical and Biosocial Anthropology, 35, 43-47.

[19] Ziaei, S., Moghasemi, M., & Faghihzadeh, S. (2010). Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women. Climacteric: the journal of the International Menopause Society, 13(2), 147-156.
How to Cite
HorbatiukО., ShatkovskaА., Dudikova, L., BinkovskaА., Vaskiv, O., Gerich, O., Pryimak, I., & Harbuziuk, V. (2022). Correction of sexual dysfunction in postmenopausal women. Reports of Vinnytsia National Medical University, 26(1), 130-134.